CoronaryAtlas logo
CoronaryAtlas
Bradykinin
Pathway / Coagulation & thrombus formation

Bradykinin

peptide

Kallikrein-generated vasodilatory mediator providing endothelial signaling and cardioprotection during acute thrombosis.

Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencemedium
RationaleContact-phase activation byproduct; vasodilation and cardioprotection in acute injury.
Also acts inEndothelial activation/erosion
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresShared / rises in both
R — rupture / Type-I
67
C — non-Type-I
71
A — assay feasibility
66
E — evidence strength
60
T1DI (composite)
19
Specificity differential (R−C)-3.8
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
2sepsis / systemic inflammationmag 2
2anemia / acute blood lossmag 3
2hypovolemia / dehydrationmag 2
2tachyarrhythmiamag 2
2hypoxemia / respiratory failuren/a
2hypertensive emergencymag 2
2high-demand / peri-operative stressmag 3
3sudden cardiac deathn/a
4aPCI-related periproceduralmag 1
4bstent thrombosisn/a
4cin-stent restenosisn/a
5CABG-relatedmag 2
Coverage: 8/12 axes with evidence
Tier: deep-scored (abstract-extracted) · 12 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Competitive/sandwich immunoassay or LC-MS/MS
Reagent / substrate
Anti-peptide antibody; or isotope-labeled internal standard (MS)
Platform
Immunoassay / LC-MS/MS
Turnaround · availability
Send-out / research · Research-grade

Literature evidence(2)

Clinical trials(1)